申请人:Takeda Pharmaceutical Company Limited
公开号:EP2781513A1
公开(公告)日:2014-09-24
The present invention provides a compound selected from
2-((3,4-Dimethoxyphenyl)-1-methyl-4-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)piperazine or a salt thereof;
1-[4-(Methylsulfonyl)phenyl]-4-(2,4,6,7-tetramethyl-2,3-dihydro-1-benzofuran-5-yl)pi perazine or a salt thereof;
4-[4-(2,4,6,7-Tetramethyl-2,3-dihydro-1-benzofuran-5-yl)piperazin-1-yl]benzamide or a salt thereof;
1-((3,4-Dimethoxyphenyl)-4-(2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)pip erazine or a salt thereof;
1-((4-Methoxyphenyl)-4-(7-methoxy-2,4,6-trimethyl-2,3-dihydro-1-benzofuran-5-yl)pi perazine or a salt thereof;
1-4-[4-(2,2,4,6,7-Pentamethyl-2,3-dihydro-1-benzofuran-5-yl)piperazin-1-yl]phenyl}ethanone or a salt thereof;
5-[4-(4-Methoxyphenyl)piperazin-1-yl]-2,4,6,7-tetramethyl-2,3-dihydro-1-benzofuran-2-yl}methanol or a salt thereof;
1-((2,4-Dimethoxyphenyl)-4-(2,4,6,7-tetramethyl-2,3-dihydro-1-benzofuran-5-yl)pipera zine or a salt thereof; and
1-((2,2,4,6,7-pentamethyl-2,3-dihydro-1-benzofuran-5-yl)-4-(1H-pyrazole-3-yl)piperazine or a salt thereof.
本发明提供的化合物选自
2-((3,4-二甲氧基苯基)-1-甲基-4-(2,2,4,6,7-五甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪或其盐;
1-[4-(甲磺酰基)苯基]-4-(2,4,6,7-四甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪或其盐;
4-[4-(2,4,6,7-四甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪-1-基]苯甲酰胺或其盐;
1-((3,4-二甲氧基苯基)-4-(2,2,4,6,7-五甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪或其盐;
1-((4-甲氧基苯基)-4-(7-甲氧基-2,4,6-三甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪或其盐;
1-4-[4-(2,2,4,6,7-五甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪-1-基]苯基}乙酮或其盐;
5-[4-(4-甲氧基苯基)哌嗪-1-基]-2,4,6,7-四甲基-2,3-二氢-1-苯并呋喃-2-基}甲醇或其盐;
1-((2,4-二甲氧基苯基)-4-(2,4,6,7-四甲基-2,3-二氢-1-苯并呋喃-5-基)哌嗪或其盐
1-((2,2,4,6,7-五甲基-2,3-二氢-1-苯并呋喃-5-基)-4-(1H-吡唑-3-基)哌嗪或其盐。